Janus Henderson Group PLC Sells 233,367 Shares of Glaukos Co. (NYSE:GKOS)

Janus Henderson Group PLC reduced its stake in Glaukos Co. (NYSE:GKOS - Free Report) by 17.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,092,417 shares of the medical instruments supplier's stock after selling 233,367 shares during the period. Janus Henderson Group PLC owned 1.98% of Glaukos worth $163,804,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Rhumbline Advisers raised its holdings in Glaukos by 0.3% during the 4th quarter. Rhumbline Advisers now owns 141,790 shares of the medical instruments supplier's stock valued at $21,260,000 after acquiring an additional 403 shares during the period. IFP Advisors Inc bought a new position in Glaukos in the 4th quarter worth about $43,000. US Bancorp DE grew its holdings in Glaukos by 8.3% during the 4th quarter. US Bancorp DE now owns 6,099 shares of the medical instruments supplier's stock valued at $914,000 after buying an additional 470 shares in the last quarter. CIBC Asset Management Inc bought a new stake in shares of Glaukos during the fourth quarter valued at about $227,000. Finally, Raymond James Financial Inc. purchased a new stake in shares of Glaukos in the fourth quarter worth about $16,910,000. Institutional investors own 99.04% of the company's stock.

Glaukos Stock Performance

Shares of NYSE GKOS traded up $3.83 during midday trading on Friday, hitting $95.45. The company's stock had a trading volume of 773,079 shares, compared to its average volume of 685,745. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.71 and a current ratio of 5.54. The firm has a market cap of $5.45 billion, a P/E ratio of -33.26 and a beta of 0.83. Glaukos Co. has a 1-year low of $77.10 and a 1-year high of $163.71. The firm's fifty day moving average price is $93.95 and its 200-day moving average price is $126.28.

Glaukos (NYSE:GKOS - Get Free Report) last released its earnings results on Wednesday, April 30th. The medical instruments supplier reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.33) by $0.11. Glaukos had a negative net margin of 39.04% and a negative return on equity of 16.53%. The business had revenue of $106.66 million for the quarter, compared to the consensus estimate of $102.78 million. During the same period in the previous year, the firm earned ($0.70) EPS. The business's revenue for the quarter was up 24.6% on a year-over-year basis. On average, sell-side analysts forecast that Glaukos Co. will post -1.08 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Alex R. Thurman sold 1,520 shares of the business's stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total value of $162,396.80. Following the sale, the chief financial officer now owns 53,431 shares of the company's stock, valued at $5,708,568.04. The trade was a 2.77% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.80% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on GKOS shares. Morgan Stanley reduced their target price on Glaukos from $110.00 to $72.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. Stifel Nicolaus decreased their target price on shares of Glaukos from $140.00 to $115.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. Wells Fargo & Company downgraded Glaukos from an "overweight" rating to an "equal weight" rating and cut their price target for the stock from $160.00 to $86.00 in a research note on Thursday, May 1st. Stephens cut their price target on Glaukos from $140.00 to $115.00 and set an "overweight" rating on the stock in a research note on Friday, May 2nd. Finally, Needham & Company LLC cut their price target on Glaukos from $176.00 to $115.00 and set a "buy" rating on the stock in a research note on Thursday, May 1st. One analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company's stock. According to data from MarketBeat.com, Glaukos has an average rating of "Moderate Buy" and a consensus target price of $134.67.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.